Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Deal Watch: Roche Links With SemaThera, Acquires GenMark Diagnostics

Executive Summary

Tempest goes public via a reverse merger with Millendo. Takeda inks its ninth deal of 2021, a discovery pact with BridGene around its chemoproteomics technology.

You may also be interested in...



Bausch Investors Initially Pessimistic Following B+L Spinout

With its IPO of Bausch + Lomb bringing in $630m in proceeds, Bausch Health is moving forward with its plan to use the eye care unit’s separation to pay down its remaining debt.

Bausch Hopes B+L Spin-Out Will 'Unlock' The Value Of Eye-Care Business

Bausch Health is paying down its debt with a $630m IPO for its Bausch + Lomb eyecare product business.

Big Pharma’s Busiest Deal-Makers In 2021 Were Less Prolific Than In 2020

Totals for aggregate deals and in the M&A, alliance and divestment categories were similar among the 10 busiest deal makers from 2020 to 2021, but COVID-19 may have driven a more hectic deal-making pace overall in 2020.

Related Content

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

SC144098

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel